Choose Language
Select a language for news translation.
Vertex’s cystic fibrosis drugs improve protein function but don’t fix the genetic cause, leaving a gap Sionna Therapeutics aims to fill with a therapy that cou…
ANI Pharmaceuticals reported Q2 net income of $24.71 million, up from $8.14 million a year ago, driven by a 25.9% revenue increase. This strong performance, wh…
Biocryst Pharmaceuticals Inc reported a profit of $78.4 million in Q2, significantly up from $5.09 million last year, driven by a 33.6% revenue increase to $21…
(RTTNews) - Natera, Inc. (NTRA), a genetic testing company said on Wednesday that it has filed for approval in Japan to use its Signatera test as a companion d…
Merck reported a $1.34 billion net loss in Q2 2023, prompting a cut in profit guidance due to $14.7 billion in acquisition-related charges, despite raising its…
Written by Eric Volkman for The Motley Fool -> The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.…
Written by Brendan Coffey for The Motley Fool -> 20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acqui…
On Friday, Ionis Pharmaceuticals' Director, Michael R. Hayden, made a $1.06M buy of IONS, purchasing 20,000 shares at a cost of $52.94 a piece. Ionis Pharmaceu…
